Login to Your Account

'Keytruda' PD-1 kingdom? Merck's melanoma label perplexes, disappoints

By Randy Osborne
Staff Writer

Friday, September 5, 2014

Merck & Co. Inc.'s FDA clearance, almost two months earlier than expected, of PD-1-targeting Keytruda (pembrolizumab) for melanoma holds the title for gaining the first U.S. approval of a drug in the class, but restrictions in the label have meant "a lot of head-scratching," said Robert Pierce, director in biologics at Merck and member of the PD-1 development team.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription